These findings not only validate VEGF as a promising biomarker for disease monitoring but also highlight its potential utility in guiding targeted therapeutic strategies aimed at disrupting tumor angiogenesis and improving patient outcomes in OSCC. The gene discussed is VEGFA; the disease is neoplasm.